Scientific Program

Friday, September 12, 2025

09:00-09:15 Congress Opening Hall A
Welcome message on behalf of the Congress chairpersons
Bruce Mann, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
Henry Gomez Moreno, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León Rivera, Lima, Peru  

 

09:15-10:30 Session 1: Neoadjuvant therapy Hall A
Chairpersons Henry Gomez Moreno, Lima, Peru
Bruce Mann, Melbourne, Australia
09:15-09:45
09:15
09:25
09:35
Debate: That cT1cN0 HER2+ve should have Neoadjuvant Systemic Therapy (NAST)
Yes: Javier Cortes, Madrid, Spain
No:  Richard de Boer, Melbourne, Australia
Discussion
09:45-10:00 Didactic: Imaging before and during NAST
Karla Sepulveda, Houston, TX, USA
10:00-10:30
10:00
10:10
10:20
Debate: That endocrine therapy is neoadjuvant treatment of choice for ER+ve/HER2-ve disease
Yes: Antonio Llombart, Valencia, Spain
No: Henry Gomez Moreno, Lima, Peru
Discussion

 

10:30-11:00 Coffee break, poster viewing and exhibition visit

 

11:00-12:00 Session 2: Surgery Hall A
Chairpersons  Luis Pinillos, Lima, Peru
Rafael Vázquez, Mexico City, Mexico
11:00-11:30
11:00
11:10
11:20
Debate: Breast conservation, not mastectomy, should be the standard of care for T2 cancers
Yes: Shelley Potter, Bristol, UK
No: Nereida Esparza-Arias, Mexico City, Mexico    
Discussion
11:30-12:00
11:30
11:40
11:50
Debate: Radiation therapy should be given to all women under 70 having breast conservation for invasive cancer
Yes: David Antonio Martínez Pérez, Medellin-Antioquia, Colombia
No: Mauricio León Rivera, Lima, Peru
Discussion

 

12:00-13:30 Session 3: HER2+ve disease Hall A
Chairpersons Adriana Freitas, Santa Catarina, Brazil
Javier Cortes, Madrid, Spain
12:00-12:35
12:00
12:10
12:20
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Antonio Llombart, Valencia, Spain
No: Richard de Boer, Melbourne, Australia 
Discussion
12:35-12:55
12:35
12:45
12:55
Didactic: Understanding HER2 low disease – how to diagnose/how to treat?
Diagnose: Nirmala Pathmanathan, Sydney, Australia
Treat: Jesus Schwartz,
Lima, Peru
Discussion
13:05-13:40
13:05
13:15
13:25
Debate: Axillary radiation is better than surgery after neoadjuvant treatment for node positive disease
Yes: Gustavo Luyo, Lima, Peru
No: Stuart McIntosh, Belfast, UK
Discussion

 

13:40-14:40 Lunch Symposium:

Lunch will be served to session participants only.

Hall A
Chairperson

 

13:40-14:40 Lunch break, poster viewing and exhibition visit

 

14:40-15:10 Session 4: Case discussions Hall A
Moderator Lia Pamela Rebaza, Lima, Peru
Panel of experts Imager: Rosa Cebrian, Lima, Peru
Medical oncologist: Zaida Morante,
Lima, Peru
Surgeon: Yanet Carrasco Rojas,
Arequipa, Peru
Radiation oncologist: Joseana Ayala,
Lima, Peru
Pathologist: Andrea Gomero,
Lima, Peru

 

 15:10-16:10 Session 5: ER+ breast cancer
Hall A
Chairpersons Enrique Bargallo, Mexico City, Mexico
Alastair Thompson, Houston, TX, USA
15:10-15:40
15:10
15:20
15:30
Debate: Post menopausal women should receive an AI in preference to Tamoxifen
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Silvia Falcon, Lima, Peru
Discussion
15:40-16:10
15:40
15:50
16:00
Debate: Postmenopausal women with clinical T1N0 ER+ breast cancer do not need axillary surgery
Yes: Lia Pamela Rebaza, Lima, Peru
No: Bruce Mann, Melbourne, Australia
Discussion

 

16:10-16:40 Coffee break, poster viewing and exhibition visit

 

16:40-17:40 Session 6: HR+ve Metastatic Breast Cancer (MBC) Hall A
Chairpersons Henry Gomez Moreno, Lima, Peru
Natalia Valdivieso, Lima, Peru
16:40-17:10
16:40
16:50
17:00
Debate: Endocrine therapy should be given as 1st line therapy for ALL patients with ER+ve MBC
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Walter Li, Lima, Peru
Discussion
17:10-17:40
17:10
17:17
17:24
17:31
Didactic: What to do after first progression of ER+ breast cancer on three continents: Change ET, CDK4/6i or SERDS?
Javier Cortes, Madrid, Spain
Richard de Boer, Melbourne, Australia
Natalia Valdivieso,Lima, Peru
Discussion

 

17:40-19:00 Poster Session and Networking Reception

 

Saturday, September 13, 2025

 08:30-09:30 Breakfast Industry Symposium
Hall A
Light refreshments will be served to session participants only.

 

 09:30-10:30 Session 7: Screening Hall A
Chairpersons Silvia Falcon, Lima, Peru
Gerardo Castorena, Mexico City, Mexico
09:30-10:00
09:30
09:40
09:50
Debate: That all countries should invest in population-based mammographic screening
Yes: Karla Sepulveda, Houston, TX, USA
No: Monique Gary, Sellersville, PA, USA 
Discussion
10:00-10:30 Didactic: Artificial Intelligence to advance breast cancer screening
Karla Sepulveda, Houston, TX, USA

 

10:30-11:00 Coffee break, poster viewing and exhibition visit

 

 

11:00-12:30 Session 8: Triple negative breast cancer Hall A
Chairpersons Richard De Boer, Melbourne, Australia
Shelley Potter, Bristol, UK
11:00-11:30
11:00
11:10
11:20
Debate: That all stage 2 TNBC patients should be treated according to the Keynote 522 regimen
Yes: Javier Cortes, Madrid, Spain
No: Henry Gomez Moreno, Lima, Peru
Discussion
11:30-12:00 Didactic: TNBC subtypes: How do we use them to help patient outcomes?
Nirmala Pathmanathan, Sydney, Australia

 

12:00-12:30 Session 9: Case Discussions Hall A
Moderator Ronald Limon, Santa Cruz de la Sierra, Bolivia
Panel of experts Imager:  Liana Falcon, Lima, Peru
Medical oncologist: Natalia Valdivieso, Lima, Peru
Surgeon: Andy Pantoja, Trujillo, Peru
Radiation oncologist: Alberto Lachos, Lima, Peru
Pathologist: Franco Doimi, Lima, Peru

 

12:30-13:30 Session 10: Reducing the risk Hall A
Chairpersons Karla Sepulveda, Houston, TX, USA
12:30-13:00
12:30
12:40
12:50
Debate: All women under 50 with gene mutations should be offered bilateral mastectomy
Yes: Lia Pamela Rebaza, Lima, Peru
No: Stuart McIntosh, Belfast, UK  
Discussion
13:00-13:30
13:00
13:10
13:20
Debate: All women presenting with nodal disease should have radiation therapy after mastectomy
Yes: Oscar Niño De Guzman, Cochabamba, Bolivia
No: Valentina Ovalle, Santiago, Chile
Discussion

 

13:30-14:30 Lunch Symposium:

Lunch will be served to session participants only.

Hall A
Chairperson

 

13:30-14:30 Lunch break, poster viewing and exhibition visit

 

14:30-16:00 Session 11: Adjuvant endocrine therapy Hall A
Chairpersons Nirmala Pathmanathan, Sydney, Australia
Rafael Vázquez, Mexico City, Mexico
14:30-15:10 Pitching the test in five minutes: Why this test is “best”?
14:30

14:40

14:50

15:00

PAM50: Javier Cortes, Madrid, Spain

Oncotytpe/ODX: Henry Gomez Moreno, Lima, Peru

Mammaprint: Alastair Thompson, Houston, TX, USA

Pathology: Henry GuerraLima, Peru

15:10-15:30 Didactic: Risk assessment (summary) for ER+ breast cancer
Antonio Llombart, Valencia, Spain
15:30-16:00
15:30
15:40
15:50
Debate: That all young women treated with OFS should be given an aromatase inhibitor
Yes: Alastair Thompson, Houston, TX, USA
No: Richard De Boer, Melbourne, Australia
Discussion

 

16:00-17:00 Session 12: Locoregional management Hall A
Chairpersons Lia Pamela Rebaza, Lima, Peru
16:00-16:30
16:00
16:10
16:20
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Enrique Bargallo, Mexico City, Mexico
No: Bruce Mann, Melbourne, Australia
Discussion
16:30-17:00  Case discussions: Focusing on Locoregional management
Moderator Mauricio León Rivera, Lima, Peru
Panel of experts Medical oncologist: Luis Orrego, Lima, Peru
Imager: Pilar Montenegro, Lima, Peru
Surgeon: Oscar Niño De Guzman, Cochabamba, Bolivia
Radiation oncologist: Juan Manuel Trejo, Lima, Peru
Pathologist: Henry Guerra, Lima, Peru

 

 17:00-17:15 Congress closing and Award presentation Hall A
Bruce Mann, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
Henry Gomez Moreno, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León Rivera, Lima, Peru    
  • Program is subject to change
Skip to content